TOP > 外国特許検索 > ANTI-HEPATITIS B VIRUS AGENT

ANTI-HEPATITIS B VIRUS AGENT UPDATE

外国特許コード F180009608
整理番号 5562
掲載日 2018年11月16日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP031825
国際公開番号 WO 2018043747
国際出願日 平成29年9月4日(2017.9.4)
国際公開日 平成30年3月8日(2018.3.8)
優先権データ
  • 特願2016-173023 (2016.9.5) JP
発明の名称 (英語) ANTI-HEPATITIS B VIRUS AGENT UPDATE
発明の概要(英語) Provided is an anti-hepatitis B virus drug which comprises a compound having a specific structure or a salt thereof and can exhibit an interferon-like activity.
従来技術、競合技術の概要(英語) BACKGROUND ART
(HBV) hepatitis B viral infection duration the user 1% of the population in Japan (about 100 million people), the world is 7% (about 4 million) of the population estimates and, chronic hepatitis, cirrhosis, hepatocellular carcinoma, failure of the wafer for effective therapeutic agent is infected with the need for development.
Current, is the treatment of hepatitis B, interferon (IFN) a nucleic acid analog formulation used in the formulation.Nucleic acid analogs (for example, entecavir tenofovir and the like) is formulated, HBV infection in the progeny of the virus of the liver cells to form a viral gene inhibits HBV polymerase essential to, the appearance of drug-resistant virus has been a problem.HBV DNA is, to produce a covalently closed circular DNA by the polymerase (cccDNA) the virus and to be repaired, the template and the cccDNA, the synthesis of viral RNA, mRNA as a part, HBs antigen, antigen HBe, HBc antigen of the virus that is required to form the translation of the protein are used.However, the remaining liver cells infected with HBV cccDNA easily, it may be difficult to provide the HBV and complete, the patient's life, which must continue to drink the therapeutic agent is a problem that the (non-patent document 1).
IFN is, the secretion of cytokines in the immune cells one 1, and activate immune cells, viral life cycle of the action at various points along the function of suppressing the growth of the virus.Current, generally alpha (pegylated interferon: Peg-IFN) and can be used in clinical, treatment of hepatitis B performance is improved.However, Peg-IFN treatment effect is obtained for the cases, HBe antigen positive, negative at about 30% regardless of, as well as various side effects have been reported, in the high-invasive injection formulation, such as are many problems remain.
In order to overcome these problems, the non-nucleic acid low molecular weight anti-virus system has been under research and development of the therapeutic agent.For example, IFN HCV replicon cell is used as the pseudo-agent, RO8191 (Non-Patent Document 2) and its related compounds (Non-Patent Document 3, Patent Document 1) is reported, any of the cytotoxic compounds, the solubility, such as pharmacokinetic suffers from the problem.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO UNIVERSITY
  • 発明者(英語)
  • Hideaki Kakeya
  • Nobutake
  • Kyohei Hayashi
  • Kojima Satoshi
  • Hirotaya
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close